Binding model for nonpeptide antagonists of alpha(v)beta(3) integrin

Area of Science:

• Biochemistry
• Structural Biology
• Medicinal Chemistry

Background:

• Integrins are crucial cell surface receptors involved in various biological processes.
• Integrin alpha(v)beta(3) is a key target for therapeutic intervention in diseases like cancer and osteoporosis.
• Selective antagonists for alpha(v)beta(3) over alpha(IIb)beta(3) are needed to minimize side effects.

Purpose of the Study:

• To develop a computational binding model for nonpeptide antagonists of integrin alpha(v)beta(3).
• To identify key molecular interactions responsible for selective antagonism of alpha(v)beta(3) over alpha(IIb)beta(3).
• To provide a structural basis for the design of novel, potent, and selective alpha(v)beta(3) antagonists.

Main Methods:

• Molecular docking analyses were performed using the MMFFs force field.
• The crystal structure of integrin alpha(v)beta(3) (PDB ID: 1JV2) was utilized.
• Computational modeling was employed to predict binding modes and interactions.

Main Results:

• A novel binding model for selective alpha(v)beta(3) antagonists was identified.
• Four distinct chemical classes of antagonists exhibited similar binding modes.
• Key interactions include basic nitrogen with D150 (alpha(v)) and carboxylic acid with R214 (beta(3)).
• A favorable pi-pi stacking interaction with Y178 (alpha(v)) was observed for potent antagonists.

Conclusions:

• The proposed binding model accurately explains the activity of alpha(v)beta(3) selective antagonists.
• The model is consistent with experimental data, including mutagenicity and photoaffinity cross-linking studies.
• This study provides valuable insights for the rational design of next-generation integrin alpha(v)beta(3) therapeutics.